Provided herein are compositions and methods for targeted treatment of Aspergillus-associated diseases and disorders in mammals, such as diseases and disorders associated with Aspergillus infection.

This invention is directed to vaccine compositions and methods of using the same to prevent infection.

Provided, herein, in certain embodiments are virus-like particles such as synthetic enveloped VLPs or synthetic membrane VLPs. In some embodiments, the VLPs comprise a lipid bilayer. In some embodiments, the VLPs comprise a purified antigen anchored to the lipid bilayer. Some embodiments relate to vaccines comprising the VLP, methods of using the vaccine, and methods of making the vaccine or VLP.

The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.

Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

The invention generally provides methods of treating or preventing infection and/or disease associated with different fungal pathogens in a subject in need, using an isolated antiserum generated against an immunogenic peptide of one fungal pathogen that contains antibodies that cross-protect the subject from infection and/or disease associated with one or more different fungal pathogens. The antiserum may be generated against a Kexin peptide derived from one of a Pneumocystis, Aspergillus, Candida, or Cryptococcus fungal pathogen. The resulting cross-protective, isolated antiserum may be used as a therapeutic for treating or protecting a subject who receives the antiserum against infection and/or disease associated with multiple fungal pathogens, in addition to the pathogen against which the antiserum is generated. Also provided are compositions and kits for detecting or quantifying the presence of antibodies directed against a Kex peptide of one, two, three, or more of Pneumocystis, Aspergillus, Candida, or Cryptococcus in a subject.

The present disclosure provides a method of purifying polysaccharides from a cell lysate, comprising partially purifying the cell lysate comprising an impurity and a polysaccharide to obtain a clarified cmde lysate; mixing the clarified crude lysate with a neutralization solution comprising a salt to form a neutralized lysate; mixing the neutralized lysate with a precipitation solution comprising cetyltrimethylammonium bromide to form a first supernatant and a first precipitate; and separating the first precipitate from the first supernatant, wherein the polysaccharide is located in the first supernatant. The present disclosure further provides a method of making a polysaccharide vaccine. Also provided are vaccines, delivery systems, compositions and polysaccharides made by the methods described herein.

The present invention relates to a composition comprising antigenic material of keratinophilic fungi and/or keratinophilic yeasts for use in a method of treating and/or preventing hoof- and claw diseases in animals and a new Trichophyton verrucosum strain which can e.g. be used in such a method of treatment and/or prevention.

Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens.

The invention generally provides methods of treating or preventing aspergillosis disease and/or its symptoms associated with infection by the Aspergillus pathogenic fungus. The methods involve administering an Aspergillus Kexin peptide, or a composition comprising an Aspergillus peptide, to a mammalian subject in need thereof, such as a subject afflicted with aspergillus, or a subject susceptible to or at risk of infection by Aspergillus and ensuing aspergillosis disease. In some aspects, the Aspergillus Kexin peptide is an A. fumigatus Kexin peptide. In some aspects, the mammalian subject is a human patient. In some aspects, the patient is immunosuppressed or immunocompromised. The Aspergillus Kexin peptide as immunogen or vaccine generates a potent and robust immune response, e.g., antibody response, in the immunized subject. The methods afford therapeutic and protective treatment against aspergillosis and its symptoms, as well as a reduction in the severity of aspergillosis in the treated subjects.